Literature DB >> 21632042

Affective lability in bipolar disorder and borderline personality disorder.

D Bradford Reich1, Mary C Zanarini, Garrett Fitzmaurice.   

Abstract

BACKGROUND: The boundaries between the affective instability in bipolar disorder and borderline personality disorder have not been clearly defined. Using self-report measures, previous research has suggested that the affective lability of patients with bipolar disorder and borderline personality disorder may have different characteristics.
METHODS: We assessed the mood states of 29 subjects meeting Revised Diagnostic Interview for Borderlines and Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for BPD and 25 subjects meeting DSM-IV criteria for bipolar II disorder or cyclothymia using the Affective Lability Scale (ALS), the Affect Intensity Measure (AIM), and a newly developed clinician-administered instrument, the Affective Lability Interview for Borderline Personality Disorder (ALI-BPD). The ALI-BPD measures frequency and intensity of shifts in 8 affective dimensions. Subjects in the borderline group could not meet criteria for bipolar disorder; subjects in the bipolar/cyclothymia group could not meet criteria for BPD.
RESULTS: Patients in the bipolar group had significantly higher scores on the euthymia-elation subscale of the ALS; patients in the BPD group had significantly higher scores on the anxiety-depression subscale of the ALS. Patients with bipolar disorder had significantly higher total AIM scores and significantly higher score on the AIM positive emotion subscale. In terms of frequency, patients in the borderline group reported the following: (1) significantly less frequent affective shifts between euthymia-elation and depression-elation on the ALI-BPD and (2) significantly more frequent shifts between euthymia-anger, anxiety-depression, and depression-anxiety. In terms of intensity, borderline patients reported the following: (1) significantly less intense shifts between euthymia-elation and depression-elation on the ALI-BPD and (2) significantly more intense shifts between euthymia-anxiety, euthymia-anger, anxiety-depression, and depression-anxiety.
CONCLUSION: The affective lability of patients with borderline and bipolar II/cyclothymic can be differentiated with respect to frequency and intensity using both self-report and clinician-administered measures.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21632042     DOI: 10.1016/j.comppsych.2011.04.003

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  13 in total

1.  Amygdala Resting State Connectivity Differences between Bipolar II and Borderline Personality Disorders.

Authors:  D Bradford Reich; Emily L Belleau; Christina M Temes; Atilla Gonenc; Diego A Pizzagalli; Staci A Gruber
Journal:  Neuropsychobiology       Date:  2019-09-25       Impact factor: 2.328

2.  Affective lability in offspring of parents with major depressive disorder, bipolar disorder and schizophrenia.

Authors:  Alyson Zwicker; Vladislav Drobinin; Lynn E MacKenzie; Emily Howes Vallis; Victoria C Patterson; Jill Cumby; Lukas Propper; Sabina Abidi; Alexa Bagnell; Barbara Pavlova; Martin Alda; Rudolf Uher
Journal:  Eur Child Adolesc Psychiatry       Date:  2019-06-06       Impact factor: 4.785

3.  Borderline personality disorder in transition age youth with bipolar disorder.

Authors:  S Yen; E Frazier; H Hower; L M Weinstock; D R Topor; J Hunt; T R Goldstein; B I Goldstein; M K Gill; N D Ryan; M Strober; B Birmaher; M B Keller
Journal:  Acta Psychiatr Scand       Date:  2015-04-11       Impact factor: 6.392

Review 4.  Subthreshold bipolarity: diagnostic issues and challenges.

Authors:  Robin Nusslock; Ellen Frank
Journal:  Bipolar Disord       Date:  2011 Nov-Dec       Impact factor: 6.744

5.  The association between variability, intensity, and persistence of suicidal ideation and prospective suicidal behavior in the systematic treatment enhancement program for bipolar disorder (STEP-BD) study.

Authors:  Bartholt Bloomfield-Clagett; Dede K Greenstein; Carlos A Zarate; Elizabeth D Ballard
Journal:  Int J Bipolar Disord       Date:  2022-07-01

6.  Affective lability and difficulties with regulation are differentially associated with amygdala and prefrontal response in women with Borderline Personality Disorder.

Authors:  Jennifer A Silvers; Alexa D Hubbard; Emily Biggs; Jocelyn Shu; Eric Fertuck; Sadia Chaudhury; Michael F Grunebaum; Jochen Weber; Hedy Kober; Megan Chesin; Beth S Brodsky; Harold Koenigsberg; Kevin N Ochsner; Barbara Stanley
Journal:  Psychiatry Res Neuroimaging       Date:  2016-06-21       Impact factor: 2.376

7.  A familial risk enriched cohort as a platform for testing early interventions to prevent severe mental illness.

Authors:  Rudolf Uher; Jill Cumby; Lynn E MacKenzie; Jessica Morash-Conway; Jacqueline M Glover; Alice Aylott; Lukas Propper; Sabina Abidi; Alexa Bagnell; Barbara Pavlova; Tomas Hajek; David Lovas; Kathleen Pajer; William Gardner; Adrian Levy; Martin Alda
Journal:  BMC Psychiatry       Date:  2014-12-02       Impact factor: 3.630

8.  Assessment of Affect Lability: Psychometric Properties of the ALS-18.

Authors:  Anna Contardi; Claudio Imperatori; Italia Amati; Michela Balsamo; Marco Innamorati
Journal:  Front Psychol       Date:  2018-03-29

9.  Clinical Features, Neuropsychology and Neuroimaging in Bipolar and Borderline Personality Disorder: A Systematic Review of Cross-Diagnostic Studies.

Authors:  Anna Massó Rodriguez; Bridget Hogg; Itxaso Gardoki-Souto; Alicia Valiente-Gómez; Amira Trabsa; Dolores Mosquera; Aitana García-Estela; Francesc Colom; Victor Pérez; Frank Padberg; Ana Moreno-Alcázar; Benedikt Lorenz Amann
Journal:  Front Psychiatry       Date:  2021-06-09       Impact factor: 4.157

10.  Oxford Lithium Trial (OxLith) of the early affective, cognitive, neural and biochemical effects of lithium carbonate in bipolar disorder: study protocol for a randomised controlled trial.

Authors:  Kate E A Saunders; Andrea Cipriani; Jennifer Rendell; Mary-Jane Attenburrow; Natalie Nelissen; Amy C Bilderbeck; Sridhar R Vasudevan; Grant Churchill; Guy M Goodwin; Anna C Nobre; Catherine J Harmer; Paul J Harrison; John R Geddes
Journal:  Trials       Date:  2016-03-02       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.